オクトレオチド
分子式: | C49H66N10O10S2 |
その他の名称: | SMS-201-995、オクトレオチド、Octreotide、D-Phe-L-Cys(1)-L-Phe-D-Trp-L-Lys-L-Thr-L-Cys(1)-N-[(1R,2R)-2-Hydroxy-1-(hydroxymethyl)propyl]-NH2、SMS-201995、D-Phe-Cys(1)-Phe-D-Trp-Lys-Thr-Cys(1)-N-[(1R,2R)-1-(Hydroxymethyl)-2-hydroxypropyl]-NH2 |
体系名: | D-Phe-L-Cys(1)-L-Phe-D-Trp-L-Lys-L-Thr-L-Cys(1)-N-[(1R,2R)-2-ヒドロキシ-1-(ヒドロキシメチル)プロピル]-NH2、D-Phe-Cys(1)-Phe-D-Trp-Lys-Thr-Cys(1)-N-[(1R,2R)-1-(ヒドロキシメチル)-2-ヒドロキシプロピル]-NH2 |
D-Phe-L-Cys-L-Phe-D-Trp-L-Lys-L-Thr-L-Cys-N-[(1R,2R)-2-ヒドロキシ-1-(ヒドロキシメチル)プロピル]-NH2
分子式: | C49H68N10O10S2 |
その他の名称: | SMS-201-995【reduced】、Octreotide【reduced】、オクトレオチド【還元型】、D-Phe-L-Cys-L-Phe-D-Trp-L-Lys-L-Thr-L-Cys-N-[(1R,2R)-2-Hydroxy-1-(hydroxymethyl)propyl]-NH2、(2R,3R)-2-[(D-Phe-L-Cys-L-Phe-D-Trp-L-Lys-L-Thr-L-Cys-)Amino]-1,3-butanediol |
体系名: | D-Phe-L-Cys-L-Phe-D-Trp-L-Lys-L-Thr-L-Cys-N-[(1R,2R)-2-ヒドロキシ-1-(ヒドロキシメチル)プロピル]-NH2、(2R,3R)-2-[(D-Phe-L-Cys-L-Phe-D-Trp-L-Lys-L-Thr-L-Cys-)アミノ]-1,3-ブタンジオール |
オクトレオチド
オクトレオチド
出典: フリー百科事典『ウィキペディア(Wikipedia)』 (2022/12/12 09:45 UTC 版)
オクトレオチド(Octreotide)はソマトスタチン模倣オクタペプチドである。ソマトスタチンよりも成長ホルモン、グルカゴン、インスリン阻害作用が強い。商品名サンドスタチン。
- ^ a b c “サンドスタチンLAR筋注用10mg/サンドスタチンLAR筋注用20mg/サンドスタチンLAR筋注用30mg 添付文書” (2015年3月). 2015年9月15日閲覧。
- ^ a b c “サンドスタチン皮下注用 50µg/サンドスタチン皮下注用 100µg 添付文書” (2015年3月). 2015年9月15日閲覧。
- ^ Gøtzsche PC, Hróbjartsson A (2008). “Somatostatin analogues for acute bleeding oesophageal varices”. Cochrane Database Syst Rev (3): CD000193. doi:10.1002/14651858.CD000193.pub3. PMID 18677774.
- ^ Medscape: Octreoscan review
- ^ Joshua Chin, Matthew Vesnaver, Vadim Bernard-Gauthier, Erin Saucke-Lacelle, Björn Wängler, Carmen Wängler, Ralf Schirrmacher. Amino Acids: Direct one-step labeling of cysteine residues on peptides with 11C-methyl triflate for the synthesis of PET radiopharmaceuticals. Amino Acids. 2013 Aug 7. PMID 23921782
- ^ “カルチノイド腫瘍に対する放射性ソマトスタチンアナログ療法”. Nature Japan (2010年8月1日). doi:10.1038/nrendo.2010.94. 2015年9月15日閲覧。
- ^ Prasad V, Fetscher S, Baum RP. (2007). “Changing role of somatostatin receptor targeted drugs in NET: Nuclear Medicine's view.”. J Pharm Pharm Sci. 10 (2): 321s-337s. PMID 17718935 .
- ^ a b c d Haberfeld, H, ed (2009) (German). Austria-Codex (2009/2010 ed.). Vienna: Österreichischer Apothekerverlag. ISBN 3-85200-196-X
- ^ a b c d Dinnendahl, V, Fricke, U, ed (2010) (German). Arzneistoff-Profile. 8 (23 ed.). Eschborn, Germany: Govi Pharmazeutischer Verlag. ISBN 978-3-7741-9846-3
- ^ Hovind P, Simonsen L, Bülow J (March 2010). “Decreased leg glucose uptake during exercise contributes to the hyperglycaemic effect of octreotide”. Clin Physiol Funct Imaging 30 (2): 141–5. doi:10.1111/j.1475-097X.2009.00917.x. PMID 20132129.
- ^ Saif MW (July 2011). “Rheumatoid arthritis associated with the use of Sandostatin LAR depot in a patient with pancreatic neuroendocrine tumor. An association or a coincidence? The first case report”. JOP 12 (4): 425–8. PMID 21737909 . Lay summary – eHealthMe.com.
- ^ van der Lely AJ, de Herder WW, Lamberts SW (November 1997). “A risk-benefit assessment of octreotide in the treatment of acromegaly”. Drug Saf 17 (5): 317–24. doi:10.2165/00002018-199717050-00004. PMID 9391775.
- ^ Kapicioglu S, Mollamehmetoglu M, Kutlu N, Can G, Ozgur GK (January 1998). “Inhibition of penile erection in rats by a long-acting somatostatin analogue, octreotide (SMS 201-995)”. Br J Urol 81 (1): 142–5. doi:10.1046/j.1464-410x.1998.00520.x. PMID 9467491.
- ^ Klopp, T, ed (2010) (German). Arzneimittel-Interaktionen (2010/2011 ed.). Arbeitsgemeinschaft für Pharmazeutische Information. ISBN 978-3-85200-207-1
- ^ Maurer R, Gaehwiler BH, Buescher HH, Hill RC, Roemer D. Opiate antagonistic properties of an octapeptide somatostatin analog. Proceedings of the National Academy of Sciences USA. 1982 Aug;79(15):4815-7. PMID 6126877
- ^ Allen MP, Blake JF, Bryce DK, Haggan ME, Liras S, McLean S, Segelstein BE. Design, synthesis and biological evaluation of 3-amino-3-phenylpropionamide derivatives as novel mu opioid receptor ligands. Bioorganic and Medicinal Chemistry Letters. 2000 Mar 20;10(6):523-6. PMID 10741545
- ^ Subcutaneous octreotide in cluster headache: randomized placebo-controlled double-blind crossover study.
- ^ a b c d Lustig RH, Hinds PS, Ringwald-Smith K, Christensen RK, Kaste SC, Schreiber RE, Rai SN, Lensing SY, Wu S, Xiong X (June 2003). “Octreotide therapy of pediatric hypothalamic obesity: a double-blind, placebo-controlled trial”. J. Clin. Endocrinol. Metab. 88 (6): 2586–92. doi:10.1210/jc.2002-030003. PMID 12788859.
- ^ Flier JS (2004). “Obesity wars: Molecular progress confronts an expanding epidemic”. Cell 116 (2): 337–50. doi:10.1016/S0092-8674(03)01081-X. PMID 14744442.
- ^ Boulpaep, Emile L.; Boron, Walter F. (2003). Medical physiologya: A cellular and molecular approach. Philadelphia: Saunders. p. 1227. ISBN 0-7216-3256-4
- ^ Lustig RH (2011). “Hypothalamic obesity after craniopharyngioma: mechanisms, diagnosis, and treatment”. Front Endocrinol (Lausanne) 2: 60. doi:10.3389/fendo.2011.00060. PMC 3356006. PMID 22654817 .
- ^ Lustig RH, Greenway F, Velasquez-Mieyer P, Heimburger D, Schumacher D, Smith D, Smith W, Soler N, Warsi G, Berg W, Maloney J, Benedetto J, Zhu W, Hohneker J (February 2006). “A multicenter, randomized, double-blind, placebo-controlled, dose-finding trial of a long-acting formulation of octreotide in promoting weight loss in obese adults with insulin hypersecretion”. Int J Obes (Lond) 30 (2): 331–41. doi:10.1038/sj.ijo.0803074. PMC 1540404. PMID 16158082 .
- ^ Uhl W, Anghelacopoulos SE, Friess H, Büchler MW (1999). “The role of octreotide and somatostatin in acute and chronic pancreatitis”. Digestion 60 Suppl 2: 23–31. doi:10.1159/000051477. PMID 10207228.
- ^ Shima Y, Ohtsu A, Shirao K, Sasaki Y (May 2008). “Clinical efficacy and safety of octreotide (SMS201-995) in terminally ill Japanese cancer patients with malignant bowel obstruction”. Jpn. J. Clin. Oncol. 38 (5): 354–9. doi:10.1093/jjco/hyn035. PMID 18490369.
- ^ Skagen C, Einstein M, Lucey MR, Said A (Feb 2009). “Combination Treatment With Octreotide, Midodrine, and Albumin Improves Survival in Patients With Type 1 and Type 2 Hepatorenal Syndrome.”. J Clin Gastroenterol. 43 (7): 680–5. doi:10.1097/MCG.0b013e318188947c. PMID 19238094.
- ^ Patient.info (Feb 2013). Hypotension .
- ^ Kilic D, Sahin E, Gulcan O, Bolat B, Turkoz R, Hatipoglu A (2005). “Octreotide for treating chylothorax after cardiac surgery”. Tex Heart Inst J 32 (3): 437–9. PMC 1336729. PMID 16392238 .
- ^ Siu SL, Lam DS (2006). “Spontaneous neonatal chylothorax treated with octreotide”. J Paediatr Child Health 42 (1-2): 65–7. doi:10.1111/j.1440-1754.2006.00788.x. PMID 16487393.
- ^ Chan EH, Russell JL, Williams WG, Van Arsdell GS, Coles JG, McCrindle BW (November 2005). “Postoperative chylothorax after cardiothoracic surgery in children”. Ann. Thorac. Surg. 80 (5): 1864–70. doi:10.1016/j.athoracsur.2005.04.048. PMID 16242470.
- ^ Greek Researchers Investigate Octreotide Hypertension Research Foundation, accessed 2011-01-02
- ^ Panagopoulos GN, Deftereos SN, Tagaris GA, Gryllia M, Kounadi T, Karamani O, Panagiotidis D, Koutiola-Pappa E, Karageorgiou CE, Piadites G (2007). “Octreotide: a therapeutic option for idiopathic intracranial hypertension”. Neurol Neurophysiol Neurosci: 1. PMID 17700925.
- 1 オクトレオチドとは
- 2 オクトレオチドの概要
- 3 効能・効果
- 4 標的受容体
- 5 内分泌への影響
- 6 関連項目
固有名詞の分類
- オクトレオチドのページへのリンク